肠康方治疗腹泻型肠易激综合征临床研究
|
摘要
目的:观察肠康方治疗腹泻型肠易激综合征的临床疗效。方法:将60例肠易激综合征患者随机分为两组,治疗组30例,口服中药肠康方治疗,并随证加减,每日1剂,早晚分服,每次约200 ml,疗程4周,治疗前后完善IBS-SSS量表。对照组30例,口服马来酸曲美布汀胶囊,每次0.1 g,3次/d,疗程4周,治疗前后完善IBS-SSS量表。结果:治疗后两组患者各项评分均有下降,治疗组总有效22例,无效8例,临床总有效率为73.33%。对照组总有效18例,无效12例,临床总有效率为60.00%。在改善患者腹痛程度、腹痛频率方面肠康方与马来酸曲美布汀胶囊疗效相当,两组比较无统计学差异(P>0.05)。在改善患者腹胀程度、排便满意度、对生活影响方面肠康方均优于马来酸曲美布汀胶囊,两组比较有统计学差异(P〈0.05)。结论:肠康方治疗腹泻型肠易激综合征具有临床意义,能有效改善患者腹痛程度、腹痛频率、腹胀程度、排便满意度及对生活影响,与马来酸曲美布汀胶囊比较在改善腹胀、排便满意度、对生活影响方面更有优势。
Objective: To observe the clinical efficacy of Changkang prescription in the treatment of diarrhea predominant irritable bowel syndrome. Methods: 60 patients with irritable bowel syndrome were randomly divided into two groups. The treatment group(30 cases) was treated with Changkang presri-pxtion, one dose a day, taking about 200 ml each time in the morning and evening, and the course of treatment was 4 weeks. The control group(30 cases) was treated with trimebutine maleate capsule 0.1 g each time, and the course of treatment was 4 weeks before and after treatment, Good IBS-SSS scale. Results: After treatment, the scores of the two groups decreased, the total effective number of 22 patients in the treatment group, 8 ineffective, the total clinical effective rate was 73.33%, the total effective number of 18 patients in the control group, ineffective 12 patients, the total clinical effective rate was 60.00%. There was no significant difference between the two groups(P〉0.05).Improving the degree of abdominal pain, abdominal pain frequency, Changkang. Changkang recipe was superior to trimebutine maleate capsule in improving the degree of abdominal distention, defecation satisfaction and life influence, and there was significant difference between the two groups(P〈0.05). Conclusion: Changkang prescription recipe has clinical significance in treating diarrhea-predominant irritable bowel syndrome. It can effectively improve the degree of abdominal pain, frequency of abdominal pain, degree of abdominal distension, degree of defecation satisfaction and its impact on life. Compared with trimebutine maleate capsule, Changkang recipe has more advantages in improving abdominal distension, defecation satisfaction and life impact.It is suitable for clinical use.
Objective: To observe the clinical efficacy of Changkang prescription in the treatment of diarrhea predominant irritable bowel syndrome. Methods: 60 patients with irritable bowel syndrome were randomly divided into two groups. The treatment group(30 cases) was treated with Changkang presri-pxtion, one dose a day, taking about 200 ml each time in the morning and evening, and the course of treatment was 4 weeks. The control group(30 cases) was treated with trimebutine maleate capsule 0.1 g each time, and the course of treatment was 4 weeks before and after treatment, Good IBS-SSS scale. Results: After treatment, the scores of the two groups decreased, the total effective number of 22 patients in the treatment group, 8 ineffective, the total clinical effective rate was 73.33%, the total effective number of 18 patients in the control group, ineffective 12 patients, the total clinical effective rate was 60.00%. There was no significant difference between the two groups(P〉0.05).Improving the degree of abdominal pain, abdominal pain frequency, Changkang. Changkang recipe was superior to trimebutine maleate capsule in improving the degree of abdominal distention, defecation satisfaction and life influence, and there was significant difference between the two groups(P〈0.05). Conclusion: Changkang prescription recipe has clinical significance in treating diarrhea-predominant irritable bowel syndrome. It can effectively improve the degree of abdominal pain, frequency of abdominal pain, degree of abdominal distension, degree of defecation satisfaction and its impact on life. Compared with trimebutine maleate capsule, Changkang recipe has more advantages in improving abdominal distension, defecation satisfaction and life impact.It is suitable for clinical use.
引文
[1] 中华医学会消化病学分会胃肠动力学组.肠易激综合征诊断和治疗的共识意见(2007,长沙)[J].中华消化杂志,2008,28(1):38-40.
[2] Simren M, Palsson OS, Whitehead WE. Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice.Current Gastroenterology Reports. 2017;19(4):15.
[3] 姚欣, 杨云生, 赵卡冰,等. 罗马Ⅲ标准研究肠易激综合征临床特点及亚型[J].世界华人消化杂志, 2008, 16(5):563-566.
[4] Lovell R M, Ford A C. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis[J].Clinical Gastroenterology & Hepatology,2012, 10(7):712-721.e4.
[5] Mearin F, Lacy B, Chang L. Rome IV: the functional bowel disorders[J]. Gastroenterology, 2016, 150(6):1393-1407.
[6] 柯水芳, 陆敏.陆敏教授治疗腹泻型肠易激综合征经验[J].中国医药导报, 2018,33(1):99-101.
[7] Brian EA, Fermin M, Lin C, et al.Bowel Disodrers[J].Gastroenterology, 2016, 150 (5) :1393-1407.
[8] 张声生,魏玮,杨俭勤.肠易激综合征中医诊疗专家共识意见(2017)[J].中医杂志,2017,58(18):1614-1620.
[9] Francis CY, Morris J, Whorwelli PJ.The irritable bowel severity scoring system:a simple method of monitoring irritable bowel syndrome and its progress[J].Aliment Pharmacol Ther, 1997, 11 (2) :395-402.
[10] 邓平安,龚杰,袁媛.马来酸曲美布汀对肠易激综合征5-HT、SP及CGRP的影响观察[J].现代诊断与治疗,2015,26(20):4654-4655.
[11] 燕麟,周正华.腹泻型肠易激综合征的病机及治法探析[J].陕西中医,2015,36(9):1218-1219.
[12] 曹晓龙,陆敏.肠康方治疗肠易激综合征临床研究[J].南京中医药大学学报,2014,30(3):232-234.
[13] 陆敏,谢慧,樊欣钰,等.“肠康方”治疗腹泻型肠易激综合征43例临床研究[J].江苏中医药,2015,47(11):27-29.
[14] 陆夏敏.肠康方对肠易激综合征模型大鼠中枢神经系统5-羟色胺转运体的影响[D].南京:南京中医药大学, 2015.
[15] 李雪, 沈明勤.肠康方对腹泻型肠易激综合征大鼠SP,VIP的影响[J].中国实验方剂学杂志,2015,21(12):112-115.
[16] 徐君.黄芩—黄连药对与肠道菌群的相互作用研究[D].南京:南京中医药大学,2014.
[2] Simren M, Palsson OS, Whitehead WE. Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice.Current Gastroenterology Reports. 2017;19(4):15.
[3] 姚欣, 杨云生, 赵卡冰,等. 罗马Ⅲ标准研究肠易激综合征临床特点及亚型[J].世界华人消化杂志, 2008, 16(5):563-566.
[4] Lovell R M, Ford A C. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis[J].Clinical Gastroenterology & Hepatology,2012, 10(7):712-721.e4.
[5] Mearin F, Lacy B, Chang L. Rome IV: the functional bowel disorders[J]. Gastroenterology, 2016, 150(6):1393-1407.
[6] 柯水芳, 陆敏.陆敏教授治疗腹泻型肠易激综合征经验[J].中国医药导报, 2018,33(1):99-101.
[7] Brian EA, Fermin M, Lin C, et al.Bowel Disodrers[J].Gastroenterology, 2016, 150 (5) :1393-1407.
[8] 张声生,魏玮,杨俭勤.肠易激综合征中医诊疗专家共识意见(2017)[J].中医杂志,2017,58(18):1614-1620.
[9] Francis CY, Morris J, Whorwelli PJ.The irritable bowel severity scoring system:a simple method of monitoring irritable bowel syndrome and its progress[J].Aliment Pharmacol Ther, 1997, 11 (2) :395-402.
[10] 邓平安,龚杰,袁媛.马来酸曲美布汀对肠易激综合征5-HT、SP及CGRP的影响观察[J].现代诊断与治疗,2015,26(20):4654-4655.
[11] 燕麟,周正华.腹泻型肠易激综合征的病机及治法探析[J].陕西中医,2015,36(9):1218-1219.
[12] 曹晓龙,陆敏.肠康方治疗肠易激综合征临床研究[J].南京中医药大学学报,2014,30(3):232-234.
[13] 陆敏,谢慧,樊欣钰,等.“肠康方”治疗腹泻型肠易激综合征43例临床研究[J].江苏中医药,2015,47(11):27-29.
[14] 陆夏敏.肠康方对肠易激综合征模型大鼠中枢神经系统5-羟色胺转运体的影响[D].南京:南京中医药大学, 2015.
[15] 李雪, 沈明勤.肠康方对腹泻型肠易激综合征大鼠SP,VIP的影响[J].中国实验方剂学杂志,2015,21(12):112-115.
[16] 徐君.黄芩—黄连药对与肠道菌群的相互作用研究[D].南京:南京中医药大学,2014.